Substantial effect of topical cidofovir 1% on recalcitrant warts in a renal-transplanted adolescent: A case report

Transplantation

Volumn 91, Issue 7, 2011, Pages

  Kralund, Henrik H ^a   Broesby Olsen, Sigurd ^a   Bistrup, Claus ^a   Lorentzen, Henrik F ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DERMATOLOGICAL AGENT; IMIQUIMOD; KERATINOLYTIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; CASE REPORT; CRYOTHERAPY; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; KIDNEY TUBULE FUNCTION; LETTER; MALE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; VERRUCA VULGARIS;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ANTIVIRAL AGENTS; CYTOSINE; HUMANS; KIDNEY TRANSPLANTATION; MALE; PHOSPHONIC ACIDS; SKIN DISEASES; WARTS;

EID: 79954615179     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31820f08d0     Document Type: Letter

References (11)

1. Chakrabarti S, Collingham KE, Osman H, et al. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant 2001; 28: 879.
2. Snoeck R, De Clercq E. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr Opin Investig Drugs 2002; 3: 1561.
3. Snoeck R, Andrei G, De Clercq E. Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg 2001; 63: 93.
4. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60: 183.
5. Bonatti H, Aigner F, De Clercq E, et al. Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl Int 2007; 20: 238.
6. Field S, Irvine AD, Kirby B. The treatment of viral warts with topical cidofovir 1%: Our experience of seven paediatric patients. Br J Dermatol 2009; 160: 223.
7. Cusack C, Fitzgerald D, Clayton TM, et al. Successful treatment of florid cutaneous warts with intravenous cidofovir in an 11- year-old girl. Pediatr Dermatol 2008; 25: 387.
8. Bhadri VA, Lee-Horn L, Shaw PJ. Safety and tolerability of cidofovir in high-risk pediatric patients. Transpl Infect Dis 2009; 11: 373.
9. Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002; 73: 661.
10. Ortiz A, Justo P, Sanz A, et al. Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir Ther 2005; 10: 185.
11. Momper JD, Zhang S, Randhawa PS, et al. Determination of cidofovir in human plasma after low dose drug administration using highperformance liquid chromatography-tandem mass spectrometry. JPharmBiomed Anal 2010; 53: 1015.